March/April Issue of Vein Specialist
JVSVL 2023 Goals
Ruth Bush, MD, JD, MPH
Editor-in-Chief, JVS-VL
President Elect, American Venous Forum
Anil Hingorani, MD
Associate Editor,
JVS-VL
Member, AVF Newsletter Committee
Anahita Dua, MD, MS, MBA, FACS
Assistant Editor, JVS-VL
Arjun Jayaraj, MD, FACS
Associate Editor, JVS-VL
Chair, AVF Annual Program Committee
Ruth Bush, MD, JD, MPH
Editor-in-Chief, JVS-VL
President Elect, American Venous Forum
Anil Hingorani, MD
Associate Editor, JVS-VL
Member, AVF Newsletter Committee
Anahita Dua, MD, MS, MBA, FACS
Assistant Editor, JVS-VL
Arjun Jayaraj, MD, FACS
Associate Editor, JVS-VL
Chair, AVF Annual Program Committee
As we come to celebrate the 10th anniversary of the Journal of Vascular Surgery—Venous and Lymphatic Disorders (JVSVL), the editors of the JVSVL are indebted to the prior editors and editorial staff of the JVS journals for the excellent foundation they have established for all of the JVS journals. Going forward, we have set some goals for 2023 for the JVSVL that may affect our readers, reviewers, and authors. By working toward these goals, we hope to:
- Enhance author experience by decreasing turnaround time (time from submission to completion of 1stround of reviews). Part of this process is to allow expedited reviews by the editorial staff for selected papers.
- Increase the number of submissions while increasing quality and rigor of research published:
- Align with groups that treat venous and lymphatic disease.
- Consider special issues to call for or invite articles on specific topics. Some authors have already been contacted regarding this goal!
- Increase the JVSVL impact factor. While the impact factor for the JVSVL has increased to 4.19, and the JVSVL is the leading journal in the venous space, we believe that we can even go higher!
- Enhance the journal through social media and outreach. This includes aligning with other JVS journals to improve marketing for all. We are developing a social media plan. On our social media platforms, we have been highlighting articles from the JVSVL. Thanks to the tireless work of Dr Dua, our number of followers on Twitter continues to increase every month. It is now more than 1000! Please follow us on Twitter: @JVSVL
- Engage a diverse group of trainees – students, residents/fellows, junior faculty–in JVSVL opportunities. This includes reviewers, authors, and the JVS interns. We have been inviting new reviewers from diverse backgrounds to help with this goal including those in community practice, young practitioners, and those from the international community. Thank you to those who have agreed. If you are interested in becoming a reviewer for the JVSVL, please email: [email protected]
- Possibly increase the annual number of issues for JVSVL. If you are interested in submitting your article, case report, experimental research, or vascular image focused on venous or lymphatic disease, please submit it to the JVSVL : https://www.editorialmanager.com/jvsvl/default1.aspx
- Transition to open access. This will allow the JVSVL to be accessible to anyone, which will greatly enhance our potential to share new ideas, techniques, tools, and data.
Sincerely,
The JVSVL Editorial Team
VEIN Platform Study (Venous Leg UlcErs:
Management and Eradication)
Alun Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh
Imperial College London – VEIN Co-Chief Investigator
Sarah Onida, PhD, FRCSVasc
Imperial College London – VEIN Co-Chief Investigator
Francine Heatley, PhD
Imperial College London, VEIN Trial Manager
Alun Davies, MA,DM,DSc,FRCS,FHEA,FEBVS,FACPh
Imperial College London – VEIN Co-Chief Investigator
Sarah Onida, PhD,,FRCSVasc
Imperial College London – VEIN Co-Chief Investigator
Francine Heatley, PhD
Imperial College London, VEIN Trial Manager
Despite its burden, venous leg ulceration has not been at the fore of cardiovascular research prioritization, with attention having historically concentrated on arterial disease. This is now changing! The Section of Vascular Surgery at Imperial College London, led by Professor Alun Davies, has been awarded a grant from National Institute of Health Research in the UK to design the VEIN Platform Study (Venous leg ulcErs: management and eradication). The grant will be developed over the next 9 months, leading to a commissioned grant submission in November 2023.
The aim of the project is to develop an optimal strategy for the development of a platform for the delivery of trials evaluating the clinical and cost effectiveness of interventions for venous leg ulcer (VLU) prevention and healing.
The project will be delivered via 5 key work streams (WS):
• WS 1 – evidence synthesis, identification of research priority areas and potential PICO
• WS 2 – establishment of the key study members
• WS 3 – identification of key performance indicators, core outcomes, and infrastructure required
• WS 4 – consensus on the optimal design, methodology, and delivery of the research
• WS 5 – submission of a platform trial funding application
To design the platform infrastructure, we are forming a core group of clinical representatives and special advisory groups from national and international societies championing venous leg ulcer care and research. We would like these core stakeholders to suggest research themes, to include aid with recruitment, and help shape the future of the platform. The methodology will be patient centric and include qualitative and quantitative approaches as well as a health economic component and ambitious global dissemination plans. If you are interested in collaborating in this exciting initiative and being at the forefront of how trials will be performed in the future, please get in touch by emailing [email protected] or [email protected] to register your interest.
What are platform trials?
Platform or multi-arm multi-stage (MAM) trials use a single adaptable infrastructure to deliver randomized controlled trials. They use a single control arm with multiple arms and interventions to answer multiple questions simultaneously and permit the addition or removal of arms to allow the inclusion of novel therapies or removal of non-performing arms. The advantages of these trials are numerous and allow for a more efficient and pragmatic approach to RCTs.
An illustration of a platform trial.
Reproduced from Jay J.H. Park, Ofir Harari, Louis Dron, Richard T. Lester, Kristian Thorlund, Edward J. Mills, An overview of platform trials with a checklist for clinical readers, Journal of Clinical Epidemiology, Volume 125, 2020, Pages 1-8, ISSN 0895-4356:
The Healthy Veins Book featured in Venous Edge
The Healthy Veins Book was featured in Venous Edge. Watch this video to hear from editor Dr John Blebea and Dr Bev Chan to learn more about the book!
Welcome New AVF Members
January/February 2023
First Name |
Last Name |
Country |
---|---|---|
Noel |
Corrales |
Guatemala |
Paul |
Feldman |
United States |
Neel |
Gadhoke |
United States |
Jonathan |
Greifenkamp |
United States |
Ashley |
Gutwein |
United States |
Georges |
Haidar |
United States |
Eric |
Heil |
United States |
Chase |
Hoffman |
United States |
Daniel |
Kaufman |
United States |
Kiran |
Kumar |
United States |
David |
Ladden |
United States |
Alexandra |
Mansour |
United States |
Mattea |
Pellerito |
United States |
Justin |
Robbins |
United States |
Stanley |
Rockson |
United States |
Elaine |
Schuessler |
United States |
Danielle |
Shaholli |
United States |
Mihae |
Shin-Diep |
United States |
Patrick |
Sullivan |
United States |
Tara |
Vandenberg |
United States |
Oscar |
Villegas-Cabello |
Mexico |
Zachary |
Williams |
United States |